ABVC vs. LGVN, ACHL, EYEN, PLUR, CUE, ORGS, ICCC, DARE, ALTS, and SRZN
Should you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Longeveron (LGVN), Achilles Therapeutics (ACHL), Eyenovia (EYEN), Pluri (PLUR), Cue Biopharma (CUE), Orgenesis (ORGS), ImmuCell (ICCC), Daré Bioscience (DARE), Janone (ALTS), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry.
Longeveron (NASDAQ:LGVN) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
Longeveron has a net margin of -1,513.83% compared to ABVC BioPharma's net margin of -8,363.97%. ABVC BioPharma's return on equity of -139.97% beat Longeveron's return on equity.
Longeveron received 12 more outperform votes than ABVC BioPharma when rated by MarketBeat users.
Longeveron presently has a consensus price target of $8.00, suggesting a potential upside of 284.62%. Given Longeveron's higher possible upside, equities research analysts plainly believe Longeveron is more favorable than ABVC BioPharma.
ABVC BioPharma has lower revenue, but higher earnings than Longeveron. ABVC BioPharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
10.0% of Longeveron shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 19.1% of Longeveron shares are held by company insiders. Comparatively, 11.9% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Longeveron has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
In the previous week, Longeveron and Longeveron both had 2 articles in the media. Longeveron's average media sentiment score of 0.96 beat ABVC BioPharma's score of 0.43 indicating that Longeveron is being referred to more favorably in the media.
Summary
Longeveron beats ABVC BioPharma on 8 of the 15 factors compared between the two stocks.
Get ABVC BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABVC BioPharma Competitors List
Related Companies and Tools
